CN115944702B - A Chinese medicinal composition for treating cerebrovascular diseases and its sequelae - Google Patents
A Chinese medicinal composition for treating cerebrovascular diseases and its sequelae Download PDFInfo
- Publication number
- CN115944702B CN115944702B CN202310188270.9A CN202310188270A CN115944702B CN 115944702 B CN115944702 B CN 115944702B CN 202310188270 A CN202310188270 A CN 202310188270A CN 115944702 B CN115944702 B CN 115944702B
- Authority
- CN
- China
- Prior art keywords
- parts
- traditional chinese
- chinese medicine
- medicine composition
- treating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000026106 cerebrovascular disease Diseases 0.000 title claims abstract description 55
- 239000000203 mixture Substances 0.000 title claims abstract description 35
- 239000003814 drug Substances 0.000 claims abstract description 53
- 206010008118 cerebral infarction Diseases 0.000 claims abstract description 39
- 241000305492 Gastrodia Species 0.000 claims abstract description 8
- 241000132012 Atractylodes Species 0.000 claims abstract description 7
- 241001522129 Pinellia Species 0.000 claims abstract description 7
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 6
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 6
- 244000273928 Zingiber officinale Species 0.000 claims abstract description 6
- 235000006886 Zingiber officinale Nutrition 0.000 claims abstract description 6
- 235000008397 ginger Nutrition 0.000 claims abstract description 6
- 241000258920 Chilopoda Species 0.000 claims abstract description 5
- 244000077995 Coix lacryma jobi Species 0.000 claims abstract description 5
- 241000361919 Metaphire sieboldi Species 0.000 claims abstract description 5
- 241000239226 Scorpiones Species 0.000 claims abstract description 5
- 241000212322 Levisticum officinale Species 0.000 claims abstract description 4
- 239000001645 levisticum officinale Substances 0.000 claims abstract description 4
- 241000213006 Angelica dahurica Species 0.000 claims abstract description 3
- 238000002360 preparation method Methods 0.000 claims description 15
- 244000197580 Poria cocos Species 0.000 claims description 4
- 235000008599 Poria cocos Nutrition 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 4
- 235000017443 Hedysarum boreale Nutrition 0.000 claims 3
- 235000007858 Hedysarum occidentale Nutrition 0.000 claims 3
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 claims 3
- 239000002994 raw material Substances 0.000 claims 3
- 244000061520 Angelica archangelica Species 0.000 claims 2
- 235000001287 Guettarda speciosa Nutrition 0.000 claims 2
- 241000112528 Ligusticum striatum Species 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 10
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 abstract description 3
- 235000011477 liquorice Nutrition 0.000 abstract description 3
- 244000163122 Curcuma domestica Species 0.000 abstract description 2
- 235000003392 Curcuma domestica Nutrition 0.000 abstract description 2
- 235000003373 curcuma longa Nutrition 0.000 abstract description 2
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 2
- 235000013976 turmeric Nutrition 0.000 abstract description 2
- 241000700159 Rattus Species 0.000 description 51
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 30
- 210000005013 brain tissue Anatomy 0.000 description 22
- 238000001914 filtration Methods 0.000 description 16
- 229940079593 drug Drugs 0.000 description 12
- 239000000284 extract Substances 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 10
- 210000000582 semen Anatomy 0.000 description 9
- 241000243684 Lumbricus Species 0.000 description 8
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 8
- 238000010298 pulverizing process Methods 0.000 description 8
- 241000131808 Scolopendra Species 0.000 description 7
- 241000522620 Scorpio Species 0.000 description 7
- 210000004556 brain Anatomy 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 7
- 230000002757 inflammatory effect Effects 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 239000009490 scorpio Substances 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 239000012466 permeate Substances 0.000 description 6
- 206010061216 Infarction Diseases 0.000 description 5
- 108090001005 Interleukin-6 Proteins 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 230000007574 infarction Effects 0.000 description 5
- 230000036542 oxidative stress Effects 0.000 description 5
- 230000003285 pharmacodynamic effect Effects 0.000 description 5
- 208000028389 Nerve injury Diseases 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 210000003414 extremity Anatomy 0.000 description 4
- 230000008764 nerve damage Effects 0.000 description 4
- 206010008190 Cerebrovascular accident Diseases 0.000 description 3
- 208000031226 Hyperlipidaemia Diseases 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 206010062717 Increased upper airway secretion Diseases 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000002490 cerebral effect Effects 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000007971 neurological deficit Effects 0.000 description 3
- 208000026435 phlegm Diseases 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- 208000028399 Critical Illness Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 206010019468 Hemiplegia Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 238000001467 acupuncture Methods 0.000 description 2
- 210000004227 basal ganglia Anatomy 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 201000007293 brain stem infarction Diseases 0.000 description 2
- 210000001168 carotid artery common Anatomy 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000003073 embolic effect Effects 0.000 description 2
- 210000000416 exudates and transudate Anatomy 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 230000003188 neurobehavioral effect Effects 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 231100000862 numbness Toxicity 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010060965 Arterial stenosis Diseases 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 206010004542 Bezoar Diseases 0.000 description 1
- 206010065559 Cerebral arteriosclerosis Diseases 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 206010013887 Dysarthria Diseases 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 208000004044 Hypesthesia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 208000007379 Muscle Hypotonia Diseases 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 244000303379 Styrax officinalis Species 0.000 description 1
- 235000001361 Styrax officinalis Nutrition 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 235000006545 Ziziphus mauritiana Nutrition 0.000 description 1
- 244000126002 Ziziphus vulgaris Species 0.000 description 1
- 235000008529 Ziziphus vulgaris Nutrition 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 201000007201 aphasia Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 201000008247 brain infarction Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 201000002676 cerebral atherosclerosis Diseases 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 238000003958 fumigation Methods 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 235000019382 gum benzoic Nutrition 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 201000005851 intracranial arteriosclerosis Diseases 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000005977 kidney dysfunction Effects 0.000 description 1
- 208000011977 language disease Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000009251 neurologic dysfunction Effects 0.000 description 1
- 208000015015 neurological dysfunction Diseases 0.000 description 1
- 230000007658 neurological function Effects 0.000 description 1
- 206010029864 nystagmus Diseases 0.000 description 1
- 206010030875 ophthalmoplegia Diseases 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- ZRHANBBTXQZFSP-UHFFFAOYSA-M potassium;4-amino-3,5,6-trichloropyridine-2-carboxylate Chemical compound [K+].NC1=C(Cl)C(Cl)=NC(C([O-])=O)=C1Cl ZRHANBBTXQZFSP-UHFFFAOYSA-M 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000026473 slurred speech Diseases 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the technical field of traditional Chinese medicines, and in particular relates to a traditional Chinese medicine composition for treating cerebrovascular diseases and sequelae thereof. The traditional Chinese medicine composition comprises the following components: ginger processed pinellia tuber, bran-fried bighead atractylodes rhizome, tall gastrodia tuber, indian buead, coix seed, chinese angelica, szechuan lovage rhizome, earthworm, turmeric root-tuber, scorpion, roasted liquorice and centipede. The traditional Chinese medicine composition has remarkable curative effect in treating cerebral infarction and cerebral infarction sequela.
Description
Technical Field
The invention belongs to the technical field of traditional Chinese medicines, and in particular relates to a traditional Chinese medicine composition for treating cerebrovascular diseases and sequelae thereof.
Background
Cerebral infarction, which is one of the most common types of cerebrovascular diseases, is a critical illness, accounts for about 70% of all acute cerebrovascular diseases, and is prone to obvious sequelae, and the proportion of female to male patients is 1: about 1. Cerebral infarction is a cerebrovascular disease that causes cerebral arterial lumen stenosis due to cerebral atherosclerosis, and further causes arterial stenosis or total occlusion due to local thrombosis due to various factors, resulting in ischemia, hypoxia, necrosis of brain tissue, and neurological dysfunction. The main factors of cerebral infarction are hypertension, coronary heart disease, diabetes, overweight, hyperlipidemia, preference for eating fat, etc., in addition, many patients have family history, and are mostly seen in middle-aged and aged people of 45-70 years, the premonitory symptoms are usually very slight, have short duration and are usually ignored by people, but some cerebral infarction delay treatment endangers life, so the cerebral infarction should be vigilant and treated as early as possible.
Cerebral infarction belongs to a critical illness and is prone to obvious sequelae:
first, the occurrence probability of sequelae of patients with limb symptoms and cerebral infarction is very high, and more common sequelae mainly include systemic symptoms such as hemiplegia, limb dyskinesia, limb numbness and the like, and even ataxia can occur, so that the body cannot normally move.
Second, other symptoms: because of the damaged brain tissue function, part of patients have language disorder, aphasia can be caused in serious cases, meanwhile, the adverse reactions of askew eyes, dysphagia and choking water can be also shown, the eyes have symptoms of nystagmus and external eye muscle paralysis, and the memory can be reduced.
The traditional Chinese medicine considers that the attack of cerebral infarction is mostly related to qi stagnation and blood stasis, wind phlegm upward disturbance, liver yang hyperactivity, qi and blood deficiency and liver and kidney yin deficiency, and the specific therapy comprises the following steps:
1. traditional Chinese medicine therapy: the Chinese medicine for treating cerebral infarction comprises brain-soothing pills, uterus-soothing bezoar pills, storax pills, baodan and the like, and has the functions of inducing resuscitation and refreshing;
2. acupuncture and moxibustion and massage treatment: the acupuncture treatment has unique curative effects on symptoms such as unfavorable limb activities, insensitive brains, insomnia, numbness and pain, muscle spasm or flaccidity and the like caused by cerebral infarction;
3. external treatment of traditional Chinese medicine: comprises sticking ear needle and adhesive tape on ear acupoint, squeezing, externally applying Chinese medicinal materials, fumigation and washing, etc.
Disclosure of Invention
The invention provides a traditional Chinese medicine composition for treating cerebral infarction and cerebral infarction sequela.
Specifically, the technical scheme of the invention is as follows:
the invention provides a traditional Chinese medicine composition, which comprises the following components: ginger processed pinellia tuber, bran-fried bighead atractylodes rhizome, tall gastrodia tuber, indian buead, coix seed, chinese angelica, szechuan lovage rhizome, earthworm, turmeric root-tuber, scorpion, roasted liquorice and centipede.
In a plurality of embodiments, the traditional Chinese medicine composition comprises the following components in parts by weight:
in one embodiment, the traditional Chinese medicine composition comprises the following components in parts by weight:
in one embodiment, the traditional Chinese medicine composition comprises the following components in parts by weight:
the second aim of the invention is the application of the traditional Chinese medicine composition in preparing medicines for treating cerebrovascular diseases, wherein the cerebrovascular diseases are cerebral infarction.
The third purpose of the invention is to use the traditional Chinese medicine composition in preparing medicines for treating cerebrovascular disease sequelae, wherein the cerebrovascular disease is cerebral infarction.
Furthermore, the preparation formulation of the traditional Chinese medicine composition is any clinically acceptable preparation formulation, preferably decoction.
Further, the traditional Chinese medicine composition is prepared according to a decoction method:
pulverizing rhizoma Pinelliae Preparada, atractylodis rhizoma parched with bran, rhizoma Gastrodiae, poria, coicis semen, radix Angelicae sinensis, rhizoma Ligustici Chuanxiong, lumbricus, radix Curcumae, scorpio, radix Glycyrrhizae Preparata, and Scolopendra, adding 5-8 times of water, decocting for 1-4 hr, separating, and filtering to obtain extract A; adding 3-5 times of water into the filter residue, decocting for the second time, separating and filtering to obtain an effusion B; the permeate A, B was combined and concentrated to give a concentrate.
Furthermore, the concentrate can be further added with pharmaceutically acceptable auxiliary materials to prepare clinically acceptable dosage forms according to a conventional preparation method.
Compared with the prior art, the invention has the beneficial effects that:
the traditional Chinese medicine composition provided by the invention has obvious curative effect in treating cerebral infarction and cerebral infarction sequela.
In animal experiments, the effect of the traditional Chinese medicine composition in improving the nerve injury behavior, cerebral infarction area and cerebral tissue water content of rats is explored, and the effect of the traditional Chinese medicine composition in treating cerebral infarction is obvious according to the expression data of inflammatory factors in rat oxidative stress markers, rat serum and cerebral tissue.
According to the clinical data statistics of the hospital, the total effective rate of the traditional Chinese medicine composition for treating cerebral infarction sequela is 94.28%.
Drawings
FIG. 1 is a graph showing the results of scoring rat nerve injury behavior
FIG. 2 is a graph showing the statistics of cerebral infarction area rate of rats
FIG. 3 is a statistical chart showing the difference in water content of brain tissue of rats
FIG. 4 shows the process of statistical analysis, significant difference verification of rat brain tissue water content data using SPSS 22.0 software (dependent variable 1-7 groups are blank, model, example 1, example 2, example 3, example 4, comparative example 1, respectively)
FIG. 5 shows the expression of the levels of ROS and SOD markers of oxidative stress in rats
FIG. 6 is the inflammatory factor (TNF-. Alpha., IL-6) levels in rat serum and brain tissue
Detailed Description
The present invention will be further described with reference to examples for the purpose of making the objects and technical aspects of the present invention more apparent, but the scope of the present invention is not limited to these examples, which are only for explaining the present invention. It will be understood by those skilled in the art that variations or equivalent substitutions that do not depart from the spirit of the invention are intended to be included within the scope of the invention.
Example 1
The preparation method comprises the following steps:
pulverizing rhizoma Pinelliae Preparada, atractylodis rhizoma parched with bran, rhizoma Gastrodiae, poria, coicis semen, radix Angelicae sinensis, rhizoma Ligustici Chuanxiong, lumbricus, radix Curcumae, scorpio, radix Glycyrrhizae Preparata, and Scolopendra, adding 6 times of water, decocting for 2 hr, separating, and filtering to obtain extract A; adding 4 times of water into the filter residue, performing secondary decoction, separating and filtering to obtain an effusion B; the permeate A, B was combined and concentrated to 400ml to give a decoction.
Example 2
The preparation method comprises the following steps:
pulverizing rhizoma Pinelliae Preparada, atractylodis rhizoma parched with bran, rhizoma Gastrodiae, poria, coicis semen, radix Angelicae sinensis, rhizoma Ligustici Chuanxiong, lumbricus, radix Curcumae, scorpio, radix Glycyrrhizae Preparata, and Scolopendra, adding 6 times of water, decocting for 2 hr, separating, and filtering to obtain extract A; adding 4 times of water into the filter residue, performing secondary decoction, separating and filtering to obtain an effusion B; the permeate A, B was combined and concentrated to 400ml to give a decoction.
Example 3
The preparation method comprises the following steps:
pulverizing rhizoma Pinelliae Preparada, atractylodis rhizoma parched with bran, rhizoma Gastrodiae, poria, coicis semen, radix Angelicae sinensis, rhizoma Ligustici Chuanxiong, lumbricus, radix Curcumae, scorpio, radix Glycyrrhizae Preparata, and Scolopendra, adding 5 times of water, decocting for 4 hr, separating, and filtering to obtain extract A; adding 3 times of water into the filter residue, performing secondary decoction, separating and filtering to obtain an effusion B; the permeate A, B was combined and concentrated to 400ml to give a decoction.
Example 4
The preparation method comprises the following steps:
pulverizing rhizoma Pinelliae Preparada, atractylodis rhizoma parched with bran, rhizoma Gastrodiae, poria, coicis semen, radix Angelicae sinensis, rhizoma Ligustici Chuanxiong, lumbricus, radix Curcumae, scorpio, radix Glycyrrhizae Preparata, and Scolopendra, adding 8 times of water, decocting for 1 hr, separating, and filtering to obtain extract A; adding 5 times of water into the filter residue, performing secondary decoction, separating and filtering to obtain an effusion B; the permeate A, B was combined and concentrated to 400ml to give a decoction.
Example 5
The preparation method comprises the following steps:
pulverizing rhizoma Pinelliae Preparada, atractylodis rhizoma parched with bran, rhizoma Gastrodiae, poria, coicis semen, radix Angelicae sinensis, rhizoma Ligustici Chuanxiong, lumbricus, radix Curcumae, scorpio, radix Glycyrrhizae Preparata, and Scolopendra, adding 6 times of water, decocting for 3 hr, separating, and filtering to obtain extract A; adding 4 times of water into the filter residue, performing secondary decoction, separating and filtering to obtain an effusion B; mixing the exudates A, B, concentrating, adding syrup and sodium benzoate, adding water to a certain amount, stirring, bottling, and sterilizing to obtain oral liquid.
Example 6
The preparation method comprises the following steps:
pulverizing rhizoma Pinelliae Preparada, atractylodis rhizoma parched with bran, rhizoma Gastrodiae, poria, coicis semen, radix Angelicae sinensis, rhizoma Ligustici Chuanxiong, lumbricus, radix Curcumae, scorpio, radix Glycyrrhizae Preparata, and Scolopendra, adding 6 times of water, decocting for 2 hr, separating, and filtering to obtain extract A; adding 4 times of water into the filter residue, performing secondary decoction, separating and filtering to obtain an effusion B; mixing the exudates A, B, concentrating into fluid extract, adding syrup, dissolving, mixing, and concentrating to obtain the soft extract.
Comparative example 1: modified ban Xia Bai Gastrodia decoction for inducing resuscitation and activating blood circulation
The preparation method comprises the following steps:
pulverizing rhizoma Pinelliae, rhizoma Atractylodis, atractylodis rhizoma, rhizoma Gastrodiae, pericarpium Citri Tangerinae, poria, coicis semen, semen Persicae, carthami flos, radix Angelicae sinensis, radix Paeoniae Rubra, rhizoma Ligustici Chuanxiong, fructus Aurantii, lumbricus and radix Curcumae, adding 6 times of water, decocting for 2 hr, separating, and filtering to obtain extract A; adding 4 times of water into the filter residue, performing secondary decoction, separating and filtering to obtain an effusion B; the permeate A, B was combined and concentrated to 400ml to give a decoction.
Pharmacodynamic experiments
In order to verify the application and mechanism of the traditional Chinese medicine composition in treating cerebral infarction diseases, the inventor develops related pharmacodynamic experimental research. The medicine selected by the following pharmacodynamic tests is a representative formula and a medicine obtained by the preparation method of the invention; the inventor also performs pharmacodynamic experiments on other medicines obtained by other formulas and preparation methods, and experimental results show that the medicines obtained by other formulas and preparation methods have the same or similar effects, but are not exhaustive due to space limitations.
The following experimental study is carried out on the basis of the safety of the drug proved by an acute toxicity test and a long-term toxicity test, and the administration dosage in the experimental study is within the safe dosage range.
The Chinese medicinal composition has the treatment effect on experimental cerebral infarction rats
1 Material
1.1 animals:
SD rats, SPF grade, 180-220g, experimental animal license number: SYXK 2018 0008 was adapted for one week prior to the experiment.
1.2 medicaments
1.2.1 medicaments
Example 1 decoction of the present invention, example 2 decoction of the present invention, example 3 decoction of the present invention, example 4 decoction of the present invention, and comparative example 1 decoction.
1.2.2 doses
The invention of example 1: 13.59g/kg (calculated as crude drug)
The invention of example 2 decoction: 13.86g/kg (calculated as crude drug)
The invention of example 3: 6.30g/kg (calculated by crude drug amount)
The invention of example 4 decoction: 16.65g/kg (calculated by crude drug amount)
Comparative example 1 decoction: 15.21g/kg (calculated as crude drug)
2. Modeling, grouping and administration
2.1 method of Forming mold
The molding method comprises the following steps: 70 rats were anesthetized, the hearts of the rats were bled, the rats were left at room temperature for 48 hours to form a thrombus, the clot was aspirated by a syringe and injected into physiological saline, and the above steps were repeated 3 times to form a small embolic suspension. The ICA was injected from the Common Carotid Artery (CCA) by aspiration of 0.2ml (embolic 100-250 μm), and multiple cerebral infarcts in the brain were formed. TTC staining method is used for checking whether the modeling is successful, and 65 rat cerebral cortex appears white infarct focus.
2.2 grouping
A total of 65 rats were successfully modeled, and the rats were randomly divided into model group, example 1 group, example 2 group, example 3 group, example 4 group, and comparative example 1 group, each group having 10 rats.
Blank 10 rats were subjected to sham surgery.
2.3 administration of drugs
The example 1 group, the example 2 group, the example 3 group, the example 4 group and the comparative example 1 group are respectively given with corresponding drugs according to the administration doses of 1.2.2; the blank group and the model group were administered with an equal amount of physiological saline, and the administration was performed intragastrically for 14d.
3. Project index detection
3.1 rat neurobehavioral injury
The rat was dosed with 14d by Longa for neurological scoring, single blind was selected, the rat's neurological behavior was assessed by two experimental persons blinded to the study, rat tail was lifted, the extension of the rat's forelimbs was observed, and the ground walking of the rat was observed, and neurological deficit symptoms were recorded with positive correlation of score to neurological impairment.
TABLE 1 rat neurobehavioral injury scoring criteria
3.2 cerebral infarct size in rats
Dosing 14d, transferring the brain tissues of each group of rats to a refrigerator at the temperature of minus 20 ℃ for 20min, slicing, treating each slice to be about 2mm thick, transferring the brain slices to a container filled with 2% TTC, covering with tinfoil paper, transferring to a water bath kettle at the temperature of 37 ℃ for 15min, incubating for dyeing under the dark condition, flushing the brain slices with normal saline after the completion, transferring to a 4% paraformaldehyde solution for fixation, shooting, measuring cerebral infarction area by using Image Pro Plus, and calculating cerebral infarction area ratio:
cerebral infarction area ratio = total cerebral infarction area/total brain platelet area x 100%
3.3 rat brain tissue Water content
Administration 14d, taking brain tissue of each group of rats, and measuring the water content. The brain tissue was transferred to tinfoil (peeled) and weighed, wherein the weight difference between the two was the brain wet weight of the rat. The brain tissue is wrapped by tinfoil and then transferred to a 100 ℃ oven for 24 hours, and then taken out to room temperature, and then is weighed twice, and the weight of the brain tissue is the dry weight of the rat brain. Calculating the water content of brain tissue of the rat:
brain tissue moisture content= (brain tissue wet weight-brain tissue dry weight)/wet weight×100%
3.4 oxidative stress marker detection
Taking fresh hemispheres of the rats of each group, weighing, grinding, adding physiological saline with the mass of 9 times to prepare homogenate, centrifuging, taking supernatant, and measuring the content of ROS and SOD by adopting a specific enzyme-linked immunosorbent assay (ELISA) kit.
3.5 inflammatory factors in rat serum and brain tissue
The levels of inflammatory factors (TNF-. Alpha., IL-6) in rat serum and brain tissue were detected using a specific ELISA kit.
4. Statistics of test results
Fig. 1 is a comparison of the results of the nerve injury behavior scores of rats, and compared with the model group, the nerve behavior score of rats administered with each embodiment of the invention is obviously reduced, and the results are obviously different, so that the traditional Chinese medicine composition disclosed by the embodiment of the invention can obviously reduce and relieve the nerve injury of rats after cerebral infarction.
Fig. 2 is a statistical result of cerebral infarction area rate of rats, showing that compared with the model group, the cerebral infarction area rate of rats in each example group of the present invention is significantly reduced, P <0.01, and the results have significant differences.
Fig. 3 is a statistical chart of the significant difference of the water content of the brain tissue of the rat, and after 14d administration, the water content of the brain tissue of the rat in each example group of the present invention is reduced compared with that of the model group, and fig. 4 is a statistical analysis and significant difference verification process of the water content data of the brain tissue of the rat by adopting SPSS 22.0 software, showing that the water content of P <0.01 in each example group of the present invention is significantly different from that of the model group in each example 1, example 2, example 3, and example 4. The dependent variables 1-7 in FIG. 4 are, in order, blank, model, example 1, example 2, example 3, example 4, and comparative example 1.
FIG. 5 shows the expression of the levels of the rat oxidative stress markers ROS and SOD. The results show that after 14d of administration, the ROS content of the oxidative stress markers of rats of each group of examples of the invention is significantly reduced, with a significant difference in P <0.01 compared to the model group; the SOD content of the oxidation stress marker of the rats in each group of examples is obviously increased, and compared with the model group, the SOD content of the rats has obvious difference with P < 0.01.
FIG. 6 shows the levels of inflammatory factors (TNF-. Alpha., IL-6) in rat serum and brain tissue. The content of inflammatory factors (TNF-alpha and IL-6) in the rat serum and brain tissue after molding is obviously increased, and the content of the inflammatory factors TNF-alpha and IL-6 in the rat serum and brain tissue of each example group of the invention is obviously reduced after 14d administration, compared with the model group, the P is less than 0.01, and the difference is obvious.
Note that: the pharmacodynamics data adopts SPSS 22.0 software to carry out statistical analysis on the obtained data, and the data is measuredN=10, expressed as P<The difference of 0.05 is statistically significant, and P is represented by<0.01。
Clinical case statistics of treatment effect of the traditional Chinese medicine composition on cerebral infarction sequela
1 Standard
1.1 diagnostic criteria for TCM
Meets the diagnosis standard of apoplexy with excessive phlegm and fire type apoplexy symptoms of apoplexy diagnosis and curative effect evaluation standard, and has the main symptoms of hemiplegia, facial distortion, slurred speech, hypoself-sensation, and the secondary symptoms of dizziness, vexation, irritability, excessive phlegm and sticky; a red tongue with yellow and greasy coating and a wiry and slippery pulse.
1.2 Western diagnostic criteria
Meets the relevant diagnosis standard in the combination of Chinese and Western medicine diagnosis and treatment guidelines for cerebral infarction.
1.3 case inclusion criteria
Meets the diagnosis standards of the traditional Chinese and western medicine, has the age of 60-80 years, is in the sequelae of cerebral infarction, namely has the onset time of more than 6 months, and patients and families agree with the study.
1.4 case exclusion criteria
Patients with severe disturbance of consciousness or mental illness; those who have liver and kidney dysfunction or malignancy; survival is expected to be less than 3 months.
2. Case data
2.1 general data
During the period of month 8 2021 to month 8 2022, 70 patients admitted to the hospital for cerebral infarction were screened for inclusion in the study, and all patients were randomized into the conventional and observation groups:
in the conventional group 35 cases: men 19, with a ratio of 54.29%, women 16, with a ratio of 45.71%, ages 60-79, average (68.83 + -5.75); infarct size: 15 cases of basal ganglia infarct patients, 12 cases of brainstem infarct patients and 8 cases of small brain infarct patients. Complications: 10 patients with hypertension, 4 patients with diabetes, and 8 patients with hyperlipidemia.
In the observation group 35 cases: 20 men, 57.14% and 15 women, 42.86% and 63-80 years old, with average (69.57 + -4.77) years old; infarct size: basal ganglia infarct patient 12, brainstem infarct patient 14, and small cerebral infarct patient 9. Complications: 13 patients with hypertension, 3 patients with diabetes, and 7 patients with hyperlipidemia.
3. Method of
3.1 methods of treatment
Conventional group: for 35 patients in conventional group, rhizoma Pinelliae, atractylodis rhizoma and rhizoma Gastrodiae decoction is used for treating, 1 dose per day, and continuous treatment for 1 month. Decoction of pinellia Tuber, atractylodes rhizome and Gastrodia Tuber: 9g of pinellia tuber, 6g of gastrodia tuber, 6g of poria cocos, 6g of exocarpium citri rubrum, 12g of bighead atractylodes rhizome, 3g of liquorice, 2 pieces of ginger and 4 pieces of Chinese date are decocted with water to obtain 400ml of decoction.
Observation group: patients in 35 observations groups were treated with the decoction of example 2, 1 dose daily, for 1 month.
3.2 observations index
The evaluation was performed by a neurological deficit score (NIHSS) which scored 0-42 points, where 0 points were normal and the patient obtained a score that was inversely related to its neurological function, with the following criteria:
TABLE 2 evaluation criteria for neurological deficit (NIHSS)
Total effective rate = (number of recovery cases + number of significant progress cases + number of progress cases)/total number of cases x 100.00%.
4. Results statistics
Table 3 comparison of efficacy after treatment for patients in conventional and observed groups (n/(%))
| Group of | Number of examples | Healing of the wound | Significant progress | Progress in progress | Invalidation of | Total effective rate |
| Conventional group | 35 | 2/(5.71) | 10/(28.57) | 17/(48.57) | 6/(17.14) | 82.85 |
| Observation group | 35 | 5/(14.28) | 15/(42.85) | 13/(37.14) | 2/(5.71) | 94.28 |
The statistics in Table 3 show that the total effective rate of the conventional group is 82.85%, the total effective rate of the observed group is 94.28%, and the total effective rate of the observed group is obviously higher than that of the conventional group.
It should be noted that only a part of the clinical statistics are presented here.
Claims (8)
1. The traditional Chinese medicine composition for treating the cerebrovascular disease is characterized by comprising the following traditional Chinese medicine raw materials in parts by weight:
3-12 parts of ginger processed pinellia tuber, 8-20 parts of bran-fried bighead atractylodes rhizome, 6-15 parts of gastrodia tuber and 10-20 parts of poria cocos
10-35 parts of coix seed, 6-15 parts of angelica, 8-20 parts of szechuan lovage rhizome and 8-15 parts of earthworm
3-10 parts of radix curcumae, 3-8 parts of scorpion, 2-10 parts of honey-fried licorice root and 3-5 parts of centipede.
2. The traditional Chinese medicine composition for treating cerebrovascular diseases according to claim 1, wherein the traditional Chinese medicine composition comprises the following traditional Chinese medicine raw materials in parts by weight:
ginger processed pinellia tuber 9 parts bran-fried bighead atractylodes rhizome 15 parts gastrodia tuber 15 parts poria cocos 15 parts
30 parts of coix seed, 12 parts of angelica, 15 parts of Ligusticum wallichii and 15 parts of earthworm
9 parts of radix curcumae, 6 parts of scorpion, 6 parts of honey-fried licorice root and 4 parts of centipede.
3. The traditional Chinese medicine composition for treating cerebrovascular diseases according to claim 1, wherein the traditional Chinese medicine composition comprises the following traditional Chinese medicine raw materials in parts by weight:
ginger processed pinellia tuber 9 parts bran-fried bighead atractylodes rhizome 12 parts gastrodia tuber 10 parts poria cocos 15 parts
30 parts of coix seed, 12 parts of Chinese angelica, 10 parts of szechuan lovage rhizome, 10 parts of earthworm
9 parts of radix curcumae, 6 parts of scorpion, 6 parts of honey-fried licorice root and 4 parts of centipede.
4. Use of a Chinese medicinal composition according to any one of claims 1-3 in the preparation of a medicament for the treatment of cerebrovascular diseases.
5. Use of a Chinese medicinal composition according to any one of claims 1-3 for the preparation of a medicament for the treatment of cerebrovascular disease sequelae.
6. The use according to claim 5, wherein the cerebrovascular disease is cerebral infarction.
7. A Chinese medicinal composition for treating cerebrovascular diseases according to any one of claims 1-3, wherein the dosage form of the Chinese medicinal composition is any clinically acceptable dosage form.
8. The traditional Chinese medicine composition for treating cerebrovascular diseases according to claim 7, wherein the dosage form is decoction.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310188270.9A CN115944702B (en) | 2023-03-02 | 2023-03-02 | A Chinese medicinal composition for treating cerebrovascular diseases and its sequelae |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310188270.9A CN115944702B (en) | 2023-03-02 | 2023-03-02 | A Chinese medicinal composition for treating cerebrovascular diseases and its sequelae |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115944702A CN115944702A (en) | 2023-04-11 |
| CN115944702B true CN115944702B (en) | 2024-02-02 |
Family
ID=87286285
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310188270.9A Active CN115944702B (en) | 2023-03-02 | 2023-03-02 | A Chinese medicinal composition for treating cerebrovascular diseases and its sequelae |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115944702B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109260415A (en) * | 2018-10-09 | 2019-01-25 | 吴蔚清 | It is a kind of for treating the Chinese medicine composition of acute cerebral infarction |
-
2023
- 2023-03-02 CN CN202310188270.9A patent/CN115944702B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109260415A (en) * | 2018-10-09 | 2019-01-25 | 吴蔚清 | It is a kind of for treating the Chinese medicine composition of acute cerebral infarction |
Non-Patent Citations (2)
| Title |
|---|
| 半夏白术天麻汤加减对急性脑梗死的疗效及其对VEGF、Ang-2和NSE水平的影响;张普娟等;贵州医药;第44卷(第08期);1289-1290 * |
| 半夏白术天麻汤治疗脑梗死的效果探究;赵少宁等;当代医药论丛;第18卷(第06期);197-198 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115944702A (en) | 2023-04-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101347557B (en) | Medicament composition for refreshment and intelligence development and preparation and use thereof | |
| CN112057501A (en) | Traditional Chinese medicine composition, traditional Chinese medicine ointment and external hot compress plaster for treating muscular atrophy and myasthenia | |
| CN104815318A (en) | Traditional Chinese medicine preparation for treating gout | |
| CN104398980A (en) | Traditional Chinese medicine preparation for treating apoplectic hemiplegia and preparation method of traditional Chinese medicine preparation | |
| CN115944702B (en) | A Chinese medicinal composition for treating cerebrovascular diseases and its sequelae | |
| CN102895387B (en) | Kidney-yang-warming medicine composition, and preparation thereof and preparation method thereof | |
| CN105012793A (en) | Preparation method of skin-wash liquid for treating vulvar cell hyperplasia | |
| CN103520427B (en) | Traditional Chinese medicine for treating body-resistance-weak and pathogen-strong type chronic osteomyelitis and preparation method thereof | |
| CN105477465A (en) | Chinese herb preparation with liver protection function and preparing technology of Chinese herb preparation | |
| CN104887950A (en) | Mastitis treatment traditional Chinese medicine compound | |
| CN104645080A (en) | Traditional Chinese medicine preparation for treating dizziness and preparation method of traditional Chinese medicine preparation | |
| CN110841007B (en) | Traditional Chinese medicine composition for treating cerebral apoplexy sequela and application thereof | |
| CN104398662A (en) | Traditional Chinese medicine preparation treating femur head necrosis and preparation technology thereof | |
| CN111375013A (en) | Traditional Chinese medicine composition for treating vertigo | |
| CN1201811C (en) | Chinese medicine composition for treating myopia and preparing method thereof | |
| CN114848724B (en) | Traditional Chinese medicine composition for treating migraine and preparation method thereof | |
| CN114617939B (en) | Traditional Chinese medicine preparation for treating ischemic cerebral apoplexy | |
| CN105920189A (en) | Traditional Chinese medicine composition for treating talalgia due to liver-kidney deficiency and preparation method thereof | |
| CN105998532A (en) | Preparation method for traditional Chinese medicine for treating Qi-stagnancy and blood stasis painful heel and composition of traditional Chinese medicine | |
| CN104940561A (en) | Traditional Chinese medicine preparation for treating eye diseases and preparing method of traditional Chinese medicine preparation | |
| CN105055816A (en) | Traditional Chinese medicine composite for treating cerebral thrombosis and preparation method thereof | |
| CN105288086A (en) | Traditional Chinese medicine composition for treating cerebral thrombosis and preparing method thereof | |
| CN104873896A (en) | Traditional Chinese medicine composition for treating stroke caused by hypertension | |
| CN104645244A (en) | Traditional Chinese medicine composition for treating atherosclerosis | |
| CN105435162A (en) | Traditional Chinese medicine composition for treating allergic rhinitis, preparation method and traditional Chinese medicine preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |